Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLIFLOFASTER
2025-521101-40-00Phase 4Authorised
- Sponsor
- CHRU Nancy
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin in chronic heart failure (CHF) and heart failure (HF) (2 arms), sponsored by CHRU Nancy. Primary endpoint: Organizational feasibility and acceptability. Planned start Mar 2026; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
chronic heart failure (CHF)heart failure (HF)
Beyond the preview
Go deeper on 2025-521101-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521101-40-00.